Can-Fite BioPharma completes RA Phase III study of lead drug candidate CF101

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it completed the design of the Rheumatoid Arthritis (RA) Phase III study of its lead drug candidate CF101.



from The Medical News http://www.news-medical.net/news/20141231/Can-Fite-BioPharma-completes-RA-Phase-III-study-of-lead-drug-candidate-CF101.aspx